SCHEMBL1464512

SCHEMBL1464512

CC(C)(C(=O)Nc1cccc(C(F)(F)F)n1)S(=O)(=O)c1ccc(Cl)nc1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CNR2 P34972 10/20 0.47
CNR1 P21554 6/20 0.45
RORC P51449 1/20 0.45
CLK4 Q9HAZ1 3/20 0.44
MAP4K4 O95819 1/20 0.44
CSNK2A1 P68400 1/20 0.44
HIPK4 Q8NE63 1/20 0.44
SRPK1 Q96SB4 2/20 0.43
RPS6KB1 P23443 1/20 0.43
CDK2 P24941 1/20 0.43
AKT2 P31751 1/20 0.43
MAPKAPK2 P49137 1/20 0.43
RPS6KA3 P51812 1/20 0.43
PLK1 P53350 1/20 0.43
PRKCD Q05655 1/20 0.43
STK3 Q13188 1/20 0.43
PIM3 Q86V86 1/20 0.43
AURKB Q96GD4 1/20 0.43
PLK3 Q9H4B4 1/20 0.43
DYRK4 Q9NR20 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1464240 0.91 CNR2 (0.48) CNR2CNR1RORCCLK4MAP4K4
SCHEMBL1465215 0.88 CNR2 (0.46) CNR2CNR1RORCCLK4MAP4K4
SCHEMBL12635982 0.87 CNR2 (0.47) CNR2CNR1RORCCLK4MAP4K4
SCHEMBL1465098 0.86 CNR2 (0.61) CNR2CNR1RORCCLK4MAP4K4
SCHEMBL1464507 0.84 TAS2R14 (0.52) CNR2CNR1RORCCLK4MAP4K4
SCHEMBL4217781 0.83 MAPK1 (0.37) CNR2CNR1RORCCLK4MAP4K4
SCHEMBL1464871 0.83 CNR2 (0.55) CNR2CNR1RORCCLK4MAP4K4
SCHEMBL1464360 0.83 CNR2 (0.50) CNR2CNR1RORCCLK4MAP4K4
SCHEMBL1464304 0.83 CNR2 (0.50) CNR2CNR1RORCCLK4MAP4K4
SCHEMBL1463834 0.83 KDM4E (0.44) CNR2CNR1RORCKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2081905-B1 SULFONYL COMPOUNDS WHICH MODULATE THE CB2 RECEPTOR BOEHRINGER INGELHEIM INT (DE) 2012-09-12 EP claimed
US-20080039464-A1 Compounds Which Modulate The CB2 Receptor BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2008-02-14 US claimed
US-8299111-B2 Compounds which modulate the CB2 receptor BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2012-10-30 US disclosed
US-8299111-B2 Compounds which modulate the CB2 receptor BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2012-10-30 US disclosed
EP-2081905-B1 SULFONYL COMPOUNDS WHICH MODULATE THE CB2 RECEPTOR BOEHRINGER INGELHEIM INT (DE) 2012-09-12 EP disclosed
US-7935715-B2 Compounds which modulate the CB2 receptor BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2011-05-03 US disclosed
US-7935715-B2 Compounds which modulate the CB2 receptor BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2011-05-03 US disclosed
US-7935715-B2 Compounds which modulate the CB2 receptor BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2011-05-03 US disclosed
US-20110071127-A1 Compounds Which Modulate the CB2 Receptor BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2011-03-24 US disclosed
US-20110071127-A1 Compounds Which Modulate the CB2 Receptor BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2011-03-24 US disclosed
US-20080039464-A1 Compounds Which Modulate The CB2 Receptor BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2008-02-14 US disclosed
US-20080039464-A1 Compounds Which Modulate The CB2 Receptor BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2008-02-14 US disclosed
US-20080039464-A1 Compounds Which Modulate The CB2 Receptor BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2008-02-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080039464-A1 Compounds Which Modulate The CB2 Receptor CNR2, CNR1, OPRL1 CNR2 1/4885CNR1 2/4885RORC 267/4885
US-20110071127-A1 Compounds Which Modulate the CB2 Receptor CNR2, CNR1, OPRL1 CNR2 1/4885CNR1 2/4885RORC 273/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.